Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

被引：0
|
作者：
De Ledinghen, V
Trimoulet, P
Winnock, M
Bernard, PH
Bourliere, M
Portal, I
Remy, AJ
Canva, V
Levy, S
Foucher, J
Chene, G
Couzigou, P
机构：
[1] Hop Haut Leveque, Pessac, France
[2] INSERM, U330, Bordeaux, France
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1655
引用
收藏
页码：586A / 586A
页数：1
相关论文
共 50 条
  • [41] Treatment with pegylated interferon alfa-2b in combination with ribavirin improved health-related quality of life compared with interferon alfa-2b plus ribavirin in chronic hepatitis C.
    Gish, R
    Rzowej, N
    Brooks, L
    Brass, C
    Weng, W
    HEPATOLOGY, 2002, 36 (04) : 582A - 582A
  • [42] A randomized trial of interferon alfa-2B, daily vs. three times a week for one month, followed by three times a week for one year in combination with ribavirin in patients who have failed a previous course of interferon.
    Gish, R
    Yao, F
    Brooks, L
    Poordad, F
    Schulze, G
    HEPATOLOGY, 1998, 28 (04) : 574A - 574A
  • [43] Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C
    Pol, S
    Nalpas, B
    Bourlière, M
    Couzigou, P
    Tran, A
    Abergel, A
    Zarski, JP
    Berthelot, P
    Bréchot, C
    HEPATOLOGY, 2000, 31 (06) : 1338 - 1344
  • [44] Sequential versus concomitant administration of ribavirin and interferon alfa-N3 in patients with chronic hepatitis C not responding to interferon alone. Results of a randomized controlled trial.
    Sostegni, R
    Ghisetti, V
    Pittaluga, F
    Marchiaro, G
    Rocca, G
    Borghesio, E
    Rizzetto, M
    Saracco, G
    GASTROENTEROLOGY, 1998, 114 (04) : A1344 - A1344
  • [45] Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C
    Jen, JF
    Glue, P
    Ezzet, F
    Chung, C
    Gupta, SK
    Jacobs, S
    Hajian, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (06) : 407 - 421
  • [46] Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
    Guilhot, F
    Chastang, C
    Michallet, M
    Guerci, A
    Harousseau, JL
    Maloisel, F
    Bouabdallah, R
    Guyotat, D
    Cheron, N
    Nicolini, F
    Abgrall, JF
    Tanzer, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04): : 223 - 229
  • [47] Interferon plus ribavirin (6 vs 12 months) in chronic hepatitis C patients non responders to interferon alone.
    Picciotto, A
    Torre, F
    Campo, N
    Giusto, R
    Brizzolara, R
    Sinelli, N
    Giudici-Cipriani, A
    Grasso, A
    De Conca, V
    Marenco, G
    Menardo, G
    Michetti, P
    HEPATOLOGY, 1999, 30 (04) : 263A - 263A
  • [48] Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone
    Sievert, W
    Batey, R
    Mollison, L
    Pianko, S
    McDonald, J
    Marinos, G
    Reed, W
    Warner, S
    Bowden, S
    De Solom, R
    Bhathal, P
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (09) : 1197 - 1204
  • [49] Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or standard combination therapy
    Chousterman, N
    Auray-Cartier, V
    Hagege, H
    Arpurt, JP
    Cassan, P
    Denis, J
    Gargot, D
    Nalet, B
    Nouel, O
    Pariente, A
    Wartelle-Bladou, C
    HEPATOLOGY, 2002, 36 (04) : 362A - 362A
  • [50] Interferon-alpha and ribavirin alone or in combination with ketoprofen for the treatment of patients with chronic hepatitis C who have not responded to previous interferon therapy.
    Nunes, FA
    Schultz, C
    Santoro, J
    Kaufman, B
    Kenny, R
    Rock, E
    Gasic, A
    Carlson, S
    Griffell, L
    Shields, D
    Matasow, G
    Lucey, MR
    HEPATOLOGY, 1999, 30 (04) : 617A - 617A
12345